Epalrica-M Tablet SR

Epalrica-M Tablet SR is a medicine used in the treatment of diabetic nerve disease. It protect the nerve fibers from damage and promotes regeneration of nerve cells. It is used along with other blood sugar lowering medications in order to prevent further nerve injury.

Epalrica-M Tablet SR may be taken with or without food, but you should try to take it at the same time every day. The dose will be decided by your doctor. Do not stop taking it without asking your doctor. If you do, your blood sugar levels may increase and put you at risk of serious complications like kidney damage and blindness. This medicine is only part of a treatment program that should include a healthy diet, regular exercise, and weight reduction as advised by your doctor.

The most common side effects of this medicine include nausea, vomiting, and increased liver enzymes. However, these are temporary and usually subside on their own. Please consult your doctor if these do not resolve or persist for a longer duration.

Before taking this medicine, inform your doctor if you have any kidney or liver problems or a urinary tract infection or if you are on water pills (diuretics). Pregnant or breastfeeding women should also consult their doctor before taking it. Avoid excessive alcohol intake while taking it as this may increase the risk of developing some side effects. Monitor your blood sugar levels regularly while taking this medicine.

• Diabetic nerve pain

Diabetic nerve pain
Epalrica-M Tablet SR is a medicine used to treat long-lasting (chronic) pain caused by nerve damage due to diabetes. It reduces pain and its associated symptoms such as mood changes, sleep problems, and tiredness. It interferes with pain signals that travel through the damaged nerves and the brain and also improves nerve conduction. Taking Epalrica-M Tablet SR regularly will improve your physical and social functioning and overall quality of life.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Nurestat-Plus

• Nausea
• Vomiting
• Increased liver enzymes

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Epalrica-M Tablet SR may be taken with or without food, but it is better to take it at a fixed time.

Epalrica-M Tablet SR is a combination of two medicines: Epalrestat and methylcobalamin which treat diabetic nerve disease. Epalrestat is an aldose reductase inhibitor. It blocks the accumulation of sorbitol in cells, which has been related in causing diabetic nerve disease. Methylcobalamin is a form of vitamin B which helps in the production of myelin, a substance that protects nerve fibers and rejuvenates damaged nerve cells.

• Take it only as per the dose and duration prescribed by your doctor.

• Adherence to antidiabetic therapy can delay the onset of or prevent diabetic nerve disease.

• Inform your doctor if you have:

  • Cut or sore on your feet that is infectious or not healing
  • Burning or tingling sensation in arm or feet that hamper your routine activities
  • Trouble in digestion, urination, or sexual functioning
  • Dizziness

• To prevent diabetic nerve pain, wear proper footwear and examine your feet every day to detect lesions early.

• Monitor your blood sugar level regularly.

• Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.

Sharma SR, Sharma N. Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective. Ann Indian Acad Neurol. 2008;11(4):231-35. [Accecssed 08 Apr. 2019] (online) Available from:

National Institues of Health. Vitamin B12. [Accessed 08 Apr. 2019] (online) Available from:

Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29(7):1538-44. [Accessed 08 Apr. 2019] (online) Available from: